Physician profile
Douglas A Schell
NPI 1235134776
$5,482.56
in general payments reported to CMS, 2019-2025
10 companies · $697 in 2025
The $697 reported for 2025 was more than what 91% of Medical-Surgical (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,979 · 2022: $429 · 2023: $694 · 2024: $684 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050 · Education: $24.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.78 |
| Education | $24.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $3,758.58 | 2021-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $379.17 | 2023-2024 | |
| Genzyme Corporation | $353.55 | 2021-2025 | |
| Biogen, INC. | $294.00 | 2022-2025 | Vumerity |
| Janssen Pharmaceuticals, INC | $221.82 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $188.00 | 2022-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $120.03 | 2025 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $86.21 | 2021 | |
| Abbvie INC. | $66.81 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $14.39 | 2025 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Schell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.